New business venture backed by Wayne Rooney receives three industry awards

New business venture backed by Wayne Rooney receives three industry awards

Swellaway Ltd, the company behind Swellaway – a patented medical device designed to treat injuries in humans and animals – has been recognised for its innovation and business potential with three coveted business awards.

Brainchild of inventor Richard Mills, Swellaway – which will initially be launched to the equine market and then shortly afterwards to consumers – works by applying cooling, heating and compression. A potential replacement for conventional treatments involving ice, water and gel packs, Swellaway prevents injuries, reduces inflammation and aids rehabilitation all in one controllable electronic wireless device.

After being awarded Winner of Next Big Thing and also Runner-Up for Product Design & Innovation in the Sheffield Chamber of Commerce’s regional awards 2014, Swellaway was pitted against other high profile category winners in the 2014 Sheffield City Region Business Awards to win The Start-up award of 2014, which was presented by Nick Hewer, Lord Sugar’s right-hand man on The Apprentice and Claire Frisby of BBC News.

“By undertaking thorough market research, including beta product development, surveys and product testing, we’ve been able to identify a massive gap in the market and closely align Swellaway with high value customer needs,” commented Richard Mills, Business Development Director at Swellaway. “Having secured backing from Manchester-based venture capitalist Acceleris Capital and other investors including Wayne Rooney, we’re now ready to start commercialising this innovative product and take it to market.”

Swellaway has already secured major interest from the largest UK equine distributor for circa 1500 units per annum.

“The interest we are generating and the high profile backing we have secured so far underlines the huge growth potential for Swellaway within several customer segments,” added Richard. “Late 2014 will see us open to a second round of funding, as we launch this game changing product and drive growth from a world-wide market opportunity.”

The Company is advised by Acceleris Capital, now part of the Seneca stable. Norman Molyneux, Chief Executive of Acceleris Capital and director at Seneca Partners, commented “We have enjoyed working with the Swellaway team and are very impressed with the product they have designed and produced. We look forward to continuing to advise the company ahead of final development and launch to the market in 2015″.

ABOUT SWELLAWAY

The Swellaway therapy wrap and wireless controller is a patented state of the art device that combines thermal, compression and sensory technology, to provide effective treatment for common musculoskeletal injuries. Utilising revolutionary technology the wrap is an electronic device, offering treatment without any pipes, water or ice.

Swellaway addresses for the first time a full player/patient management solution for injuries, sprains and strains enabling treatment from prevention through to rehabilitation all in one device. Swellaway is a game changing product that has the potential to transform the face of injury management.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.